Cosmo Pharmaceuticals N.V. (0RGI.L)
| Previous close | 63.00 |
| Open | 62.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 61.50 - 62.71 |
| 52-week range | 61.50 - 62.71 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 908.796M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
COSMO PHARMACEUTICALS N.V. and Cassiopea S.p.a. PUBLISH PROVISIONAL final RESULTS OF PUBLIC EXCHANGE OFFER FOR all publicly held shares of CASSIOPEA S.P.A.
Cosmo Pharmaceuticals N.V. / Key word(s): Takeover03-Dec-2021 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland and Lainate, Italy - 3 December 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") today announced the provisional final results for the public exchange offer by Cosmo in accordance with
- EQS Group
DETECT study shows AI assistance using GI Genius™ reduces missed polyp rate by nearly 50% on initial colonoscopy
EQS Group-News: Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous19.11.2021 / 06:00 Dublin, Ireland - November 19, 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') today announced topline results from a randomized, international, multi-center study evaluating the safety and efficacy of artificial intelligence (AI) device GI Genius(TM) as an aid for the detection of colorectal polyps in combination with colonoscopy. The DETECT study was designed to provide evidence of the
- EQS Group
COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE INTERIM RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A. AND DECLARE THE OFFER SUCCESSFUL
Cosmo Pharmaceuticals N.V. / Key word(s): Takeover18-Nov-2021 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland and Lainate, Italy - 18 November 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") today announced the following results in connection with the public exchange offer by Cosmo in Switzerl
